TerminatedPhase 2NCT02982720

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aiwu Ruth He, MD
Principal Investigator
Aiwu R. He, MD PhD
Lombardi Comprehensive Cancer Center Georgetown University
Intervention
Pembrolizumab(drug)
Enrollment
4 enrolled
Eligibility
18 years · All sexes
Timeline
20172018

Study locations (1)

Collaborators

Merck Sharp & Dohme LLC · Roswell Park Cancer Institute · The Cleveland Clinic · Georgetown University · Hoosier Cancer Research Network

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02982720 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials